ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KNSA Kiniksa Pharmaceuticals International PLC

18.61
0.16 (0.87%)
Last Updated: 14:58:24
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kiniksa Pharmaceuticals International PLC NASDAQ:KNSA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.16 0.87% 18.61 18.60 18.69 18.84 18.1174 18.50 16,940 14:58:24

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

29/05/2024 10:19pm

Edgar (US Regulatory)


 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 

Filed by the Registrant x    Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material Under §240.14a-12

 

KINIKSA PHARMACEUTICALS, LTD.

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.
¨Fee paid previously with preliminary materials.
¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

  

 

 

 

 

 

On or about May 29, 2024, the following letter was made available to shareholders eligible to vote at Kiniksa Pharmaceuticals, Ltd.'s Special Court-Ordered Meeting of Shareholders, scheduled for June 5, 2024.

 

 

 

May 29, 2024

 

Dear Kiniksa Shareholder,

 

Your vote is important and valuable to us. In connection with our upcoming Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders, we mailed you two notices with instructions on how to access the proxy materials for each such meeting and vote on the applicable proposals. As a reminder, such meetings are scheduled to take place on June 5, 2024. The definitive proxy statement related to the meetings has been filed with the SEC and can be found at www.sec.gov.

 

According to our records, your vote for the Special Court-Ordered Meeting has not yet been received.

 

Because we are holding two separate meetings, the instructions on how to access the proxy materials for each meeting contained separate control numbers. It is important to vote for both meetings, whether in person by attending the meetings or by submitting a proxy ahead of time.

 

You are strongly encouraged to vote ahead of the meetings on June 5, 2024. Please vote today by following the instructions shown on the accompanying proxy card or notice. If you are receiving this letter alongside a physical proxy card, you may vote by completing, signing and returning such proxy in the envelope provided.

 

Shareholders with questions are encouraged to contact Kiniksa’s investor relations team at IR@Kiniksa.com.

 

Sincerely,

 

/s/ Sanj K. Patel  

Chief Executive Officer and Chairman of the Board

 

 

 


1 Year Kiniksa Pharmaceuticals Chart

1 Year Kiniksa Pharmaceuticals Chart

1 Month Kiniksa Pharmaceuticals Chart

1 Month Kiniksa Pharmaceuticals Chart